Titan Pharmaceuticals misses estimates in Q2

This article was originally published here

Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results.

The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million on sales of $15 million, thanks to a one-time milestone payment following FDA approval of its buprenorphine implant, Probuphine.

Get the full story at our sister site, Drug Delivery Business News.

The post Titan Pharmaceuticals misses estimates in Q2 appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply